• Nkarta to Participate at Upcoming Investor Conferences

    Source: Nasdaq GlobeNewswire / 02 Nov 2022 07:02:00   America/Chicago

    SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at three upcoming investor conferences:

    Cowen IO Next Summit
    November 11, 2022
    10:40 a.m. ET – fireside chat

    Stifel Healthcare Conference
    November 15, 2022
    8:35 a.m. ET – fireside chat

    Evercore ISI HealthCONx Conference
    November 29, 2022
    11:20 a.m. ET – fireside chat

    A simultaneous webcast of each event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.

    About Nkarta
    Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.

    Nkarta Media/Investor Contact:
    Greg Mann
    Nkarta, Inc.
    gmann@nkartatx.com


    Primary Logo

Share on,